Vir Biotechnology (VIR) Stock Forecast & Price Target

Vir Biotechnology is supported by a compelling two-franchise story: an HDV asset base approaching an inflection with SOLSTICE showing 88% HDV RNA target-not-detected at Week 96, and a PRO-XTEN oncology platform that is increasingly validated by VIR-5500’s clean dose-escalation profile. The oncology data are especially persuasive, with 58 patients treated, no dose-limiting toxicities or maximum tolerated dose reached, 82% PSA50 and 53% PSA90 in the higher-dose cohort, and no Grade 3 cytokine release syndrome, which strengthens confidence in the dual-masking thesis and platform value. Financially, Vir has about $1.01 billion of cash and investments at June 30, supports a runway into 2H28, and the valuation framework implies roughly $3.7 billion of total firm value, with meaningful upside potential as 2026 and 2027 data readouts de-risk both franchises.

Vir Biotechnology is a clinical-stage company whose value depends on unproven programs in HDV, HBV, HIV, and oncology, yet multiple novel HBV approaches have already failed to achieve functional cure and its HDV registrational path has no FDA approval precedent. The company also faces meaningful competitive and payer risk, including Gilead’s bulevirtide expected 2026 US launch, next-generation competitors, and reimbursement uncertainty, while its HIV pipeline may not offset Biktarvy-related headwinds in the 2030s. Financially, the business still relies mainly on license rights and grants, and the outlook is further pressured by potentially greater-than-expected operating expenses and cash burn that could force equity issuance more frequently or at less attractive valuations.